共 50 条
- [43] Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1666): : 205 - 207
- [45] Efficacy and safety of risankizumab in children with Crohn's disease: A preliminary report JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1435 - I1436
- [47] Real-world effectiveness and safety of Risankizumab in Crohn's Disease JOURNAL OF CROHNS & COLITIS, 2025, 19 : I2023 - I2024
- [48] Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 213 - 223